Lipocine, Inc. (NASDAQ: LPCN) Starts Presentation at 30th Annual ROTH Conference
Lipocine (NASDAQ: LPCN) is a specialty pharmaceutical company that develops pharmaceutical products using its oral drug delivery technology in the areas of men’s and women’s health. The company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Lipocine's clinical development pipeline includes three development programs. TLANDO, designed to help restore normal testosterone levels in hypogonadal men, was well tolerated and met the primary efficacy end-points in phase 3 testing and is currently under FDA review. LPCN 1111 is being…
